Find in Library

The incidence of Transitional Cell Carcinoma (TCC) of urinary bladder is increasing worldwide. Patients with superficial TCC of urinary bladder can have a survival period of 10 years if they are detected at an early stage and appropriate intravesical adjuvant immunotherapy is instilled in time. A total number of 440 patients of superficial TCC were instilled intravesically BCG & Interferon a-2b as single drug or in combination and followed up. BCG though was most efficient, had high toxic rate while Interferon α-2b was expensive, whereas a low dose combination therapy of both showed excellent result in reducing tumor recurrences & prolonging disease pro-gression free interval. The author reviews his experience of 10 years in man-agement of these malignancies with intravesical immu-notherapy and concludes that a low dose BCG (60mg) with Interferon α-2b (5 million IU) has shown to be very effective in reducing tumor recurrences, prolonging dis-ease-progression-free interval with a very low toxicity in such patients. To achieve this a periodic maintenance dose therapy is absolutely necessary.